Single Ascending Dose Study of AMG 570 in Healthy Subjects
| Status: | Completed |
|---|---|
| Conditions: | Lupus |
| Therapuetic Areas: | Immunology / Infectious Diseases |
| Healthy: | No |
| Age Range: | 18 - 65 |
| Updated: | 9/13/2018 |
| Start Date: | March 28, 2016 |
| End Date: | September 6, 2018 |
A Randomized, Double Blind Placebo Controlled, First in Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Subcutaneous Doses of AMG 570 in Healthy Subjects
The purpose of this study is to obtain initial information on the safety and tolerability
(effects good or bad), pharmacokinetics (what the body does to the drug), and
pharmacodynamics (what the drug does to the body) of a single dose of AMG 570.
(effects good or bad), pharmacokinetics (what the body does to the drug), and
pharmacodynamics (what the drug does to the body) of a single dose of AMG 570.
Inclusion Criteria:
- Healthy as determined by the investigator
- Normal or clinically acceptable ECG
- Female subjects must be of documented non-reproductive potential
- Subjects must be current for all vaccinations
- Other inclusion criteria may apply
Exclusion Criteria:
- Current or chronic history of liver disease
- History of active infections
- History of significant respiratory disorder
- Evidence of renal disease
- Other exclusion criteria may apply
We found this trial at
3
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials